Sovaldi
Ailment: Hepatitis C
2014 U.S. Sales: $8.5 billion
Owner: Gilead Sciences
Solvadi, which treats Hepatitis C with a 90 percent cure rate, was approved by the FDA in 2013 and rapidly became one of the top-selling drugs in the United States. Its manufacturer, Gilead Sciences, has come under fire for the drug’s staggeringly high cost and its impact on budgets at Medicare and the Veterans Administration.
